EUCTR2016-005181-57-DE进行中（未招募）1 期
A randomized, placebo-controlled, double-blind study to scrutinize the efficacy of Secukinumab in patients with moderate to severe atopic dermatitis - SECU_Trial
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- GWT-TUD GmbH
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Atopic dermatitis (intrinsic disease without IgE mediated sensitization defined by negative history and negative SX-1 CAP FEIA) or extrinsic disease (defined by positive history and / or positive SX-1 CAP FEIA)*,
- •2.SCORAD index score = 25,
- •3.EASI = 16,
- •4.Male and female patients at the age of 18 to 85 years,
- •5.Signed Informed Consent,
- •6.Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed,
- •7.Subject is judged to be in good general health as determined by the principal investigator based upon the results of medical history, laboratory profile, and physical examination,
- •8.Patients with stable chronic asthma, treated with inhaled corticosteroids, will be allowed to participate.
- •*a SX-1 CAP FEIA report = 6 months is accepted
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1.Other inflammatory skin disease than atopic dermatitis,
- •2.Use of cyclosporine, azathioprine, mycophenolate [wash-out period of 4 weeks]; Phototherapy (PUVA, NB-UVB, UVA1; [wash-out period of 2 weeks]), Dupilumab (Dupixent®; [wash-out period of 12 weeks])
- •3.Subjects expected to be exposed to an undue safety risk if participating in the trial including chronic infections,
- •4.Contraindications of Secukinumab by label (i.e. approval for the treatment of psoriasis in the EU – refer to point 12, 13, 16 and 17 at the bottom of this section),
- •5.Current severe progressive or uncontrolled disease which in the judgment of the investigator renders the subject unsuitable for the trial,
- •6.Plans for administration of live vaccines during the study period,
- •7.Chronic infection,
- •8.Patients with instable chronic asthma,
- •9.Any chronic inflammatory bowel disease (e.g. Crohn’s disease),
- •10.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>10 mIU/mL),
- •11.Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unwilling to use effective contraception during the study and for 20 weeks after stopping treatment. Effective contraception is defined as either:
- •a.Barrier method: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicide (where available). Spermicides alone are not a barrier method of contraception and should not be used alone,
- •The following methods are considered more effective than the barrier method and are also acceptable:
- •b.Total abstinence: When this is in line with the preferred and usual lifestyle of the subject (Periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception),
- •c.Female sterilization: have had a surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment,
- •d.Male partner sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject,
- •e.Use of established oral, injected or implanted hormonal methods of contraception, intrauterine device (IUD) or intrauterine system (IUS) NOTE: Women are considered post-menopausal and not of child bearing potential if they have had:
- •i.12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or • six months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL
- •ii.Surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
- •12.History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening*,
- •13.Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit* (a report = 6 months is also accepted),
- •14.History of alcohol or drug abuse within 1 year of the screening visit,
- •15.Planned major surgic
研究者
相似试验
进行中（未招募）
不适用
A randomized, placebo-controlled, double-blind study on the intensity and duration of efficacy of sodium hyaluronate therapy (500-730 KDa) (HYALGAN) in the conservative treatment of Achilles tendinopathy. - NDEUCTR2010-020513-87-ITFIDIA
进行中（未招募）
1 期
A study to evaluate safety and efficacy of APO-2 at three different doses in patients with diabetic foot ulcerMedDRA version: 24.0Level: LLTClassification code 10012664Term: Diabetic foot ulcerSystem Organ Class: 100000004858Diabetic Foot UlcerEUCTR2018-001653-27-CZAposcience AG120
进行中（未招募）
1 期
Study to assess the safety and efficacy of PCN-101 in treatment-resistant depressioMedDRA version: 20.0Level: PTClassification code 10012378Term: DepressionSystem Organ Class: 10037175 - Psychiatric disordersTreatment-resistant depressionEUCTR2020-005457-25-PLPerception Neuroscience, Inc93
进行中（未招募）
1 期
A study to evaluate safety and efficacy of APO-2 at three different doses in patients with diabetic foot ulcerDiabetic Foot UlcerEUCTR2018-001653-27-DEAposcience AG132
进行中（未招募）
1 期
A randomized, placebo-controlled, double-blind study to assess the safety and efficacy of intravenous PCN-101 in treatment-resistant depressionTreatment-resistant depressionEUCTR2020-005457-25-DEPerception Neuroscience, Inc93